Trial Profile
A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2022
Price :
$35
*
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Adverse reactions; Registrational
- Acronyms REAL JP
- Sponsors Novo Nordisk
- 16 May 2022 Pooled data from NCT02229851 (REAL 1), NCT02382939 (REAL 2), NCT03075644 ( REAL JP ), published in the European Journal of Endocrinology.
- 12 Oct 2018 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Planned primary completion date changed from 28 Sep 2018 to 4 Oct 2018.